Exploring the gut microbial composition and their metabolites have been a growing interest to many researchers as a treatment target for cardiometabolic risk factors. Although we have nowadays some research performed in this field, the characteristics, and composition of "healthy" gut microbiota and the potential mechanisms involved in the effects of gut microbiota on the pathophysiological pathways of metabolic function and cardiovascular diseases (CVDs) are yet to be understood.
Importantly, lifestyle-related factors (particularly dietary components) widely affect the gut microbiota, its bacterial populations, and their diversity. In this regard, gut microbiota modulation might be one of the potential pathways through which diet-related factors such as plant-based dietary patterns, probiotic foods, prebiotics, postbiotics, and synbiotics might protect against cardiometabolic risk factors.
Besides the efficacy of targeting the gut microbiota metabolites (i.e., short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO) and lipopolysaccharides (LPS) or endotoxemia synthesis pathways) applying dietary agents has been suggested as a potential practical therapeutic approach in CVDs amelioration. in this respect, probiotics and resistant starches (prebiotics) are believed to positively affect the gut microbiota profile toward commensals; however, the mechanisms that are involved in the effects of supplementation with various probiotics strains on the host metabolic, immune, and inflammatory pathways, including SCFAs, and TMA/TMAO synthesis pathway and LPS production are yet to be defined.
In this Research Topic, we will have a collection of articles concerning the association between gut microbial composition and characteristics and cardiometabolic disorders as well as atherosclerosis risk factors. Besides, the studies on the influences of gut microbiota manipulation through dietary/pharmaceutical interventions (particularly using probiotics, prebiotics, postbiotics, or synbiotics ) in these conditions would also be collected.
Topics include but are not limited to articles, Cross-sectional, case-control, and cohort studies (and systematic reviews and meta-analysis on these studies) investigating:
The influences of gut microbiome characteristics and metabolites on cardiometabolic disorders including obesity, disrupted glycemic control, diabetes, hypertension, dyslipidemia, metabolic syndrome, fatty liver, and CVDs risk factors.
- The relationship between gut microbiota metabolites (i.e., SCFAs, TMAO and LPS or endotoxemia) and cardiometabolic indices including levels of atherogenic lipids in the serum (i.e., total cholesterol, triglycerides, LDL-C, and apolipoprotein (apo) B), HDL-C, endothelial dysfunction, or glycemic indices
Exploring the gut microbial composition and their metabolites have been a growing interest to many researchers as a treatment target for cardiometabolic risk factors. Although we have nowadays some research performed in this field, the characteristics, and composition of "healthy" gut microbiota and the potential mechanisms involved in the effects of gut microbiota on the pathophysiological pathways of metabolic function and cardiovascular diseases (CVDs) are yet to be understood.
Importantly, lifestyle-related factors (particularly dietary components) widely affect the gut microbiota, its bacterial populations, and their diversity. In this regard, gut microbiota modulation might be one of the potential pathways through which diet-related factors such as plant-based dietary patterns, probiotic foods, prebiotics, postbiotics, and synbiotics might protect against cardiometabolic risk factors.
Besides the efficacy of targeting the gut microbiota metabolites (i.e., short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO) and lipopolysaccharides (LPS) or endotoxemia synthesis pathways) applying dietary agents has been suggested as a potential practical therapeutic approach in CVDs amelioration. in this respect, probiotics and resistant starches (prebiotics) are believed to positively affect the gut microbiota profile toward commensals; however, the mechanisms that are involved in the effects of supplementation with various probiotics strains on the host metabolic, immune, and inflammatory pathways, including SCFAs, and TMA/TMAO synthesis pathway and LPS production are yet to be defined.
In this Research Topic, we will have a collection of articles concerning the association between gut microbial composition and characteristics and cardiometabolic disorders as well as atherosclerosis risk factors. Besides, the studies on the influences of gut microbiota manipulation through dietary/pharmaceutical interventions (particularly using probiotics, prebiotics, postbiotics, or synbiotics ) in these conditions would also be collected.
Topics include but are not limited to articles, Cross-sectional, case-control, and cohort studies (and systematic reviews and meta-analysis on these studies) investigating:
The influences of gut microbiome characteristics and metabolites on cardiometabolic disorders including obesity, disrupted glycemic control, diabetes, hypertension, dyslipidemia, metabolic syndrome, fatty liver, and CVDs risk factors.
- The relationship between gut microbiota metabolites (i.e., SCFAs, TMAO and LPS or endotoxemia) and cardiometabolic indices including levels of atherogenic lipids in the serum (i.e., total cholesterol, triglycerides, LDL-C, and apolipoprotein (apo) B), HDL-C, endothelial dysfunction, or glycemic indices
